Global Information
회사소개 | 문의 | 비교리스트

흡입형 약물전달 기기 : 의료기기 파이프라인 평가

Inhalable Drug Delivery Devices - Medical Devices Pipeline Assessment, 2019

리서치사 GlobalData
발행일 2019년 05월 상품 코드 851182
페이지 정보 영문 214 Pages
가격
US $ 4,000 ₩ 4,753,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 8,000 ₩ 9,507,000 PDF (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 12,000 ₩ 14,260,000 PDF (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


흡입형 약물전달 기기 : 의료기기 파이프라인 평가 Inhalable Drug Delivery Devices - Medical Devices Pipeline Assessment, 2019
발행일 : 2019년 05월 페이지 정보 : 영문 214 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 흡입형 약물전달 기기(Inhalable Drug Delivery Devices) 시장의 주요 파이프라인 제품(의료기기)과 임상시험 진행 상황에 대해 조사했으며, 제품 기능·특성 비교 분석(임상시험 진행 단계별), 주요 기업 개요 및 대표적 제품, 최근의 시장 동향(실적 보고·자본 거래 동향 등) 등의 정보를 정리하여 전해드립니다.

제1장 목차

제2장 서론

  • 흡입형 약물전달 기기 개요

제3장 임상시험중인 제품

  • 파이프라인 제품 : 임상 단계별
  • 파이프라인 제품 : 분야별
  • 파이프라인 제품 : 지역별
  • 파이프라인 제품 : 규제 경로별
  • 파이프라인 제품 : 추정 인증 시기별
  • 현재 진행중인 임상시험

제4장 임상시험중인 파이프라인 제품 : 기업별

  • 흡입형 약물전달 기기 기업 : 임상 단계별 파이프라인 제품
  • 흡입형 약물전달 기기 : 임상 단계별 파이프라인 제품

제5장 흡입형 약물전달 기기 시장 : 기업 및 제품 개요

  • Acorda Therapeutics Inc
  • Baxter International Inc
  • Bellerophon Therapeutics Inc
  • Breath Therapeutics Holding BV
  • Canigma A.L LTD
  • Edixomed Ltd
  • iDTx Systems, Inc.
  • Impel NeuroPharma Inc
  • Kanabo Research Ltd
  • Mallinckrodt Plc
  • Medical Developments International Ltd
  • Medspray BV
  • NeuroproteXeon Inc
  • Next Safety, Inc.
  • Nobilis Therapeutics Inc
  • Sandoz International GmbH
  • Texas Tech University Health Sciences Center
  • University of Texas Health Science Center at Houston
  • Vectura Group Plc
  • Vero Biotech LLC
  • VitalMIST
  • Windtree Therapeutics Inc

제6장 흡입형 약물전달 기기 시장 : 최근의 동향(총 10건)

제7장 부록

KSM 19.06.05

List of Tables

  • Table 1: Inhalable Drug Delivery Devices - Pipeline Products by Stage of Development
  • Table 2: Inhalable Drug Delivery Devices - Pipeline Products by Segment
  • Table 3: Inhalable Drug Delivery Devices - Pipeline Products by Territory
  • Table 4: Inhalable Drug Delivery Devices - Pipeline Products by Regulatory Path
  • Table 5: Inhalable Drug Delivery Devices - Pipeline Products by Estimated Approval Date
  • Table 6: Inhalable Drug Delivery Devices - Ongoing Clinical Trials
  • Table 7: Inhalable Drug Delivery Companies - Pipeline Products by Stage of Development
  • Table 8: Inhalable Drug Delivery Devices - Pipeline Products by Stage of Development
  • Table 9: Acorda Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 10: Drug Delivery Device - Neonatal Respiratory Distress Syndrome (RDS) - Product Status
  • Table 11: Drug Delivery Device - Neonatal Respiratory Distress Syndrome (RDS) - Product Description
  • Table 12: Baxter International Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 13: ProMaxx Microsphere - Product Status
  • Table 14: ProMaxx Microsphere - Product Description
  • Table 15: Bellerophon Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 16: INOpulse - Product Status
  • Table 17: INOpulse - Product Description
  • Table 18: Bellerophon Therapeutics Inc - Ongoing Clinical Trials Overview
  • Table 19: INOpulse - A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed, Inhaled Nitric Oxide in Subjects with Pulmonary Hypertension Associated with Pulmonary Fibrosis or Sarcoidosis on Long Term Oxygen Therapy Followed by an Optional Open-label Long Term Extension Safety Study
  • Table 20: INOpulse - A Phase 3, Placebo Controlled, Double-blind, Randomized, Clinical Study to Determine Efficacy, Safety, and Tolerability of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo in Symptomatic Subjects with PAH (Part 1 and Part 2)
  • Table 21: INOpulse - A Randomized, Double-blind, Placebo-controlled Dose Escalation Study to Assess the Safety and Efficacy of Pulsed iNO in Subjects with Pulmonary Hypertension Associated with Pulmonary Fibrosis on Long Term Oxygen Therapy
  • Table 22: INOpulse - An Open-label Long-term Safety Study of Inhaled Nitric Oxide (iNO) for PAH
  • Table 23: INOpulse - INOvation-2 Clinical Study of INOpulse Device
  • Table 24: INOpulse - Phase IIb Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects in Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease (PH-COPD)
  • Table 25: Breath Therapeutics Holding BV Pipeline Products & Ongoing Clinical Trials Overview
  • Table 26: Lung-Targeted BOS Device - Product Status
  • Table 27: Lung-Targeted BOS Device - Product Description
  • Table 28: Breath Therapeutics Holding BV - Ongoing Clinical Trials Overview
  • Table 29: Lung-Targeted BOS Device - A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine a (L-CsA) Inhalation Solution Delivered via the Pari Investigational eFlow Device plus Standard of Care Versus Standard of Care Alone in the Treatment of Bronchiolitis Obliterans Syndrome in Patients Post Double Lung Transplantation
  • Table 30: Lung-Targeted BOS Device - A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered Via the PARI Investigational eFlow Device Plus Standard of Care Versus Standard of Care Alone in the Treatment of Bronchiolitis Obliterans Syndrome in Patients Post Single Lung Transplantation
  • Table 31: Canigma A.L LTD Pipeline Products & Ongoing Clinical Trials Overview
  • Table 32: Vaporiser Device - Product Status
  • Table 33: Vaporiser Device - Product Description
  • Table 34: Edixomed Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 35: NOx System - Cystic Fibrosis - Product Status
  • Table 36: NOx System - Cystic Fibrosis - Product Description
  • Table 37: NOx System - VAP - Product Status
  • Table 38: NOx System - VAP - Product Description
  • Table 39: iDTx Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 40: GoPilot - Product Status
  • Table 41: GoPilot - Product Description
  • Table 42: Impel NeuroPharma Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 43: POD Device - Product Status
  • Table 44: POD Device - Product Description
  • Table 45: Impel NeuroPharma Inc - Ongoing Clinical Trials Overview
  • Table 46: POD Device - A Phase IIa, Randomized, Double Blind, Placebo Controlled, Single Ascending Dose, Safety and Pharmacokinetic/Pharmacodynamic Study of INP103 (POD L-dopa) Administered in the Presence of Benserazide to L-dopa Responsive Parkinson's Disease Patients
  • Table 47: POD Device - Comparison of Devices for Intranasal Delivery of Insulin
  • Table 48: POD Device - Open-label Study of Safety and Tolerability of Chronic Intermittent Usage for 24 or 52 Weeks of Intranasal Dihydroergotamine Mesylate (DHE) Administered Using the I123 Precision Olfactory Delivery (POD) Device [INP104, POD-DHE] in Patients with Migraine Headache: Stop 301 Trial (Safety and Tolerability of POD-DHE)
  • Table 49: Kanabo Research Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 50: Next Generation Smart VapePod MD Vaporizer - Product Status
  • Table 51: Next Generation Smart VapePod MD Vaporizer - Product Description
  • Table 52: VapePod - Product Status
  • Table 53: VapePod - Product Description
  • Table 54: Mallinckrodt Plc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 55: Next Generation Inomax Evolve - Product Status
  • Table 56: Next Generation Inomax Evolve - Product Description
  • Table 57: Medical Developments International Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 58: Penthrox Inhaler - Product Status
  • Table 59: Penthrox Inhaler - Product Description
  • Table 60: Penthrox Inhaler - Paediatric - Product Status
  • Table 61: Penthrox Inhaler - Paediatric - Product Description

List of Figures

  • Figure 1: Inhalable Drug Delivery Devices - Pipeline Products by Stage of Development
  • Figure 2: Inhalable Drug Delivery Devices - Pipeline Products by Segment
  • Figure 3: Inhalable Drug Delivery Devices - Pipeline Products by Territory
  • Figure 4: Inhalable Drug Delivery Devices - Pipeline Products by Regulatory Path
  • Figure 5: Inhalable Drug Delivery Devices - Pipeline Products by Estimated Approval Date
  • Figure 6: Inhalable Drug Delivery Devices - Ongoing Clinical Trials

GlobalData's Medical Devices sector report, "Inhalable Drug Delivery Devices - Medical Devices Pipeline Assessment, 2019" provides an overview of Inhalable Drug Delivery Devices currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Inhalable Drug Delivery Devices pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Inhalable Drug Delivery Devices under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Inhalable Drug Delivery Devices and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry.

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Inhalable Drug Delivery Devices under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Introduction

  • 2.1 Inhalable Drug Delivery Devices Overview

3 Products under Development

  • 3.1 Inhalable Drug Delivery Devices - Pipeline Products by Stage of Development
  • 3.2 Inhalable Drug Delivery Devices - Pipeline Products by Segment
  • 3.3 Inhalable Drug Delivery Devices - Pipeline Products by Territory
  • 3.4 Inhalable Drug Delivery Devices - Pipeline Products by Regulatory Path
  • 3.5 Inhalable Drug Delivery Devices - Pipeline Products by Estimated Approval Date
  • 3.6 Inhalable Drug Delivery Devices - Ongoing Clinical Trials

4 Inhalable Drug Delivery Devices - Pipeline Products under Development by Companies

  • 4.1 Inhalable Drug Delivery Devices Companies - Pipeline Products by Stage of Development
  • 4.2 Inhalable Drug Delivery Devices - Pipeline Products by Stage of Development

5 Inhalable Drug Delivery Companies and Product Overview

  • 5.1 Acorda Therapeutics Inc Company Overview
  • 5.2 Baxter International Inc Company Overview
  • 5.3 Bellerophon Therapeutics Inc Company Overview
  • 5.4 Breath Therapeutics Holding BV Company Overview
  • 5.5 Canigma A.L LTD Company Overview
  • 5.6 Edixomed Ltd Company Overview
  • 5.7 iDTx Systems, Inc. Company Overview
  • 5.8 Impel NeuroPharma Inc Company Overview
  • 5.9 Kanabo Research Ltd Company Overview
  • 5.10 Mallinckrodt Plc Company Overview
  • 5.11 Medical Developments International Ltd Company Overview
  • 5.12 Medspray BV Company Overview
  • 5.13 NeuroproteXeon Inc Company Overview
  • 5.14 Next Safety, Inc. Company Overview
  • 5.15 Nobilis Therapeutics Inc Company Overview
  • 5.16 Sandoz International GmbH Company Overview
  • 5.17 Texas Tech University Health Sciences Center Company Overview
  • 5.18 University of Texas Health Science Center at Houston Company Overview
  • 5.19 Vectura Group Plc Company Overview
  • 5.20 Vero Biotech LLC Company Overview
  • 5.21 VitalMIST Company Overview
  • 5.22 Windtree Therapeutics Inc Company Overview

6 Inhalable Drug Delivery Devices - Recent Developments

  • 6.1 Apr 30, 2019: Windtree Therapeutics appoints Daniel Geffken to Board of Directors
  • 6.2 Apr 26, 2019: AstraZeneca: Q1 2019 results
  • 6.3 Apr 25, 2019: Baxter reports first-quarter 2019 results
  • 6.4 Apr 23, 2019: Catalent invests $14 million at Its Eberbach, Germany Softgel facility
  • 6.5 Apr 12, 2019: Inhalation Sciences wins place on prestigious EU-funded Life Science Investment Hotlist
  • 6.6 Apr 11, 2019: Catalent Celebrates opening of second Shanghai facility to optimize global and local clinical supply solutions for China
  • 6.7 Apr 05, 2019: JC Pharma plans stock exchange listing to develop CannatolRx
  • 6.8 Apr 02, 2019: 3M Drug Delivery Systems relocates UK R&D to new, state-of-the-art facility
  • 6.9 Apr 01, 2019: Inhalation Sciences receives new Contract Research order for DissolvIt
  • 6.10 Apr 01, 2019: Vectura Group names Kevin Matthews to its board of directors

7 Appendix

  • 7.1 Methodology
  • 7.2 About GlobalData
  • 7.3 Contact Us
  • 7.4 Disclaimer
Back to Top
전화 문의
F A Q